医学
鼻咽癌
内科学
放化疗
肿瘤科
癌症
中性粒细胞与淋巴细胞比率
阶段(地层学)
胃肠病学
淋巴细胞
放射治疗
生物
古生物学
作者
Pooriwat Muangwong,Nontiya Homkham,Wattanapong Narueban,Chin Tadadoltip,Chayaporn Jongjumnien,Nuttida Taenawakun,Jutamas Teerapattanaphong,Imjai Chitapanarux
出处
期刊:PLOS ONE
[Public Library of Science]
日期:2023-10-09
卷期号:18 (10): e0292591-e0292591
被引量:1
标识
DOI:10.1371/journal.pone.0292591
摘要
Objective We study factors affecting neutrophil-to-lymphocyte ratio (NLR) and its changes throughout the treatment (ΔNLR) of nasopharyngeal carcinoma (NPC) underwent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy (AC) and oncological outcomes including overall survival (OS) and disease-free survival (DFS). Methods Data from 81 NPC patients was retrospectively evaluated. NLRs were obtained from first week of CCRT (pre-CCRT), last week of CCRT (end-CCRT), and at last cycle of AC (end-AC). Pre-CCRT NLR was categorized into “low” and “high”. End-CCRT and end-AC ΔNLRs were divided into “increased” and “decreased” based on NLR at these two timepoints relative to the value at pre-CCRT. Associations between sex, age, cancer stage and NLR, ΔNLRs were investigated. OS and DFS were reported. Results Median NLR at pre-CCRT (2.47) was lower than NLR at end-CCRT (6.29) and end-AC (3.77) ( P -value = 0.043). Advanced cancer stage associated with high pre-CCRT NLR ( P -value = 0.047). Male gender was associated with "increased" end-CCRT ΔNLR, whereas male gender and age ≤51 were associated with "increased" end-AC ΔNLR. Three-year OS and DFS rates were 85.25% and 76.39%, respectively. There were no statistically significant differences observed in OS and DFS among groups categorized by pre-CCRT NLR, ΔNLRs, gender, age, and cancer stage. Conclusions NLR increases during NPC treatment. Advanced staging is associated with higher baseline NLR. Increased ΔNLR is associated with male gender at end-CCRT and male gender with age ≤51 years at end-AC. No relation between NLR and its dynamic change with either OS or DFS was demonstrated.
科研通智能强力驱动
Strongly Powered by AbleSci AI